J. Lizón

发表

67 Phase II activity of gemcitabine + cisplatin in advanced non-small cell lung cancer (NSCLC)

J. Feliu, M. González-Barón, J. Dorta, 1997 .

Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer

J. Feliu, A. Pèlegrin, M. González-Barón, 2005, British Journal of Cancer.

Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma

J. Feliu, E. Casado, J. Castro, 2005, Cancer Chemotherapy and Pharmacology.

A randomized phase II trial of 5-fluorouracil, with or without human interferon-β, for advanced colorectal cancer

R. Goedkoop, J. Lizón, A. Villar-Grimalt, 1999, British Journal of Cancer.

A Prospective Randomized Trial of Continuous Infusion 5‐Fluorouracil (5‐FU) Versus 5‐FU Plus Cisplatin in Patients with Advanced Colorectal Cancer A Trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.)

A. Carrato, C. Balañà, M. Martín, 1992, American journal of clinical oncology.

Central venous brachial catheter (P.A.S. port TM) and catheter scanning system (cath‐finder TM)

J. Carles, R. Rosell, A. Alastrué, 1994, Journal of surgical oncology.

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

A. Carrato, J. Albanell, B. Munárriz, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.

E. Espinosa, J. Feliu, J. Chacón, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

E. Espinosa, S. Morales, M. González Barón, 2004, Cancer Chemotherapy and Pharmacology.

Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy

P. Martínez, M. Provencio, A. Barnadas, 1999, Cancer Chemotherapy and Pharmacology.

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

M. Ramos, S. Morales, A. Oltra, 2007, Cancer Chemotherapy and Pharmacology.

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

M. Ramos, S. Morales, A. Oltra, 2003, Cancer Chemotherapy and Pharmacology.

Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study

A. Ruíz, S. González, R. Andrés, 2017, PloS one.

Fractionated high doses (HD) of epirubicin (E) in adenocarcinoma of the lung (ADL)

A. Carrato, C. Balañà, J. Jimeno, 1991 .

Treatment of advanced colorectal cancer with recombinant interferon alpha and fluorouracil: activity in liver metastasis.

A. Antón, C. Camps, J. Jimeno, 1992, Cancer investigation.

Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis.

E. Tan, A. Szczesna, O. Bertetto, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.